...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Free
Message: A new mathematical formula for RVX
Respectfully I disagree. A big brokerage firm only launches coverage when they will make money from a large placement. To spell it out: they only get out if bed for proper $$$ like 5% of a $100m placing. They are even more conflicted than these little PR shops. And saying that its Bush League to push a stock with no revenues for several years is just plain simple BS. Lots of biotech companies at earlier clinical stages than RVX sustain much higher valuations. No, the main issue with this stock is that there is no liquidity. The rise will come, it's just a question of when.
Share
New Message
Please login to post a reply